This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Lipegfilgrastim parenteral

Updated 2 Feb 2023 | Neutropenia


Injection containing lipegfilgrastim.

This product has been produced by recombinant DNA technology using E.coli.

Drugs List

  • lipegfilgrastim 6mg/0.6ml injection
  • LONQUEX 6mg/0.6ml injection
  • Therapeutic Indications


    Reduced duration of neutropenia
    Reduced incidence of febrile neutropenia



    One 6mg dose of lipegfilgrastim is recommended 24 hours after each chemotherapy cycle.


    Children under 18 years
    Chronic myeloid leukaemia
    Hereditary fructose intolerance
    Myelodysplastic syndrome
    Secondary acute myeloid leukaemia

    Precautions and Warnings

    History of pulmonary infiltrates
    Recent history of pneumonia
    Sickle cell disease

    Incidence of thrombocytopenia and anaemia not reduced by treatment
    Treatment to be initiated and supervised by a specialist
    Presentations with sorbitol unsuitable in hereditary fructose intolerance
    For single use only
    Record name and batch number of administered product
    Monitor full blood count and differential WBC before and during therapy
    Consider splenic rupture if patient has abdominal or shoulder pain
    Monitor for symptoms of Capillary Leak Syndrome
    Monitor haematocrit values
    Monitor patients with sickle cell anaemia
    Monitor platelets
    Monitor serum potassium regularly
    Monitor spleen size
    Perform regular urinalysis
    Advise patient to seek medical advice if signs/symptoms of aortitis occur
    Antibodies to ingredient may develop
    Seek urgent medical attention if symptoms of Capillary Leak Syndrome occur
    May affect bone imaging results
    Discontinue if adult respiratory distress syndrome occurs
    Discontinue if leucocyte count exceeds 50x10 to the power of 9/L
    Discontinue if serious allergic or anaphylactic reaction occurs
    Discontinue or reduce dose if glomerulonephritis occurs
    Concurrent cytotoxic drugs: Maintain established dose regime (no increase)

    If aortitis is suspected it can usually be diagnosed by CT scan and generally resolves after withdrawal of lipegfilgrastim.

    Pregnancy and Lactation


    Lipegfilgrastim is contraindicated during pregnancy.

    The manufacturer recommends lipegfilgrastim is not used during pregnancy.

    There are very limited data on the use of lipegfilgrastim in pregnant women. Animals studies have shown reproductive toxicity.


    Lipegfilgrastim is contraindicated during breastfeeding.

    The manufacturer recommends that breastfeeding should be discontinued during treatment with lipegfilgrastim.

    It is not known whether lipegfilgrastim and its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded.

    Side Effects

    Acute febrile dermatosis (Sweet's syndrome)
    Adult respiratory distress syndrome
    Antibody formation
    Back pain
    Bone pain
    Capillary leak syndrome
    Chest pain
    Cutaneous vasculitis
    Hypersensitivity reactions
    Increase in alkaline phosphatase
    Increase in lactate dehydrogenase
    Interstitial pneumonia
    Local pain (injection site)
    Local reaction at injection site
    Pulmonary fibrosis
    Pulmonary haemorrhage
    Pulmonary infiltrates
    Pulmonary oedema
    Raised neutrophil count
    Respiratory failure
    Sickle cell crisis
    Splenic rupture

    Effects on Laboratory Tests

    Positive bone imaging findings have been associated with growth factor therapy due to the increase in haematopoietic activity in the bone marrow. This effect should be considered when bone-images are taken.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2019

    Reference Sources

    Summary of Product Characteristics: Lonquex 6mg solution for injection. Teva Pharma B.V. Revised July 2019.

    HPRA Drug Safety Update June 2018 Edition 88
    Available at:
    Last accessed: 17 September 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.